CRDF 250117 10.00C (CRDF250117C10000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

CRDF250117C10000

Watchlist

0.00
0.000.00%

15min DelayTrading Dec 26 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
GlobeNewswireDec 26 09:00 ET
While Institutions Own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), Retail Investors Are Its Largest Shareholders With 57% Ownership
Yahoo FinanceDec 23 08:13 ET
James Levine Bought 13% More Shares In Cardiff Oncology
Simply Wall StDec 21 07:56 ET
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $10
Moomoo NewsDec 17 09:31 ET · Ratings
Piper Sandler Maintains Overweight on Cardiff Oncology, Raises Price Target to $10
BenzingaDec 13 08:14 ET · Ratings
Cardiff Oncology Analyst Ratings
BenzingaDec 13 08:13 ET · Ratings

Comments

Iwill TradeScared

Dec 17 15:14

$Cardiff Oncology (CRDF.US)$ my ai 🤖 trader wrong this time 😂
Swing Trade Opportunity Summary - Score: 5.55
key attributes
Recent earnings ( No), Breakout ( No), Catalyst ( Yes), Good company ( yes), Valid float ( yes), Hot sector ( No), Near 52 week high ( No), Dollar break ( Yes)
Cardiff Oncology Inc. (CRDF) shows moderate potential based on the current worksheet analysis with a score of 5.55. The stock has some promising news catalysts, particularly the positive developments in clinical trial...